Fogarty International Center; Notice of Meeting, 41982-41983 [2021-16607]
Download as PDF
<![CDATA[
41982
Federal Register / Vol. 86, No. 147 / Wednesday, August 4, 2021 / Notices
lotter on DSK11XQN23PROD with NOTICES1
podiatry, optometry or veterinary student
with appropriate training in administering
vaccines as determined by his or her school
or training program and supervision by a
currently practicing healthcare professional
experienced in administering intramuscular
injections who administers COVID–19
vaccines that are Covered Countermeasures
under section VI of this Declaration in any
jurisdiction where the PREP Act applies in
association with a COVID–19 vaccination
effort by a State, local, Tribal or territorial
authority or by an institution in which the
COVID–19 vaccine covered countermeasure
is administered;
Subject to the following requirements:
i. The vaccine must be authorized,
approved, or licensed by the FDA;
ii. Vaccination must be ordered and
administered according to ACIP’s COVID–19
vaccine recommendation(s);
iii. The healthcare professionals and
students must have documentation of
completion of the Centers for Disease Control
and Prevention COVID–19 Vaccine Training
Modules and, if applicable, such additional
training as may be required by the State,
territory, locality, or Tribal area in which
they are prescribing, dispensing, or
administering COVID–19 vaccines;
iv. The healthcare professionals and
students must have documentation of an
observation period by a currently practicing
healthcare professional experienced in
administering intramuscular injections, and
for whom administering vaccinations is in
their ordinary scope of practice, who
confirms competency of the healthcare
provider or student in preparation and
administration of the COVID–19 vaccine(s) to
be administered and, if applicable, such
additional training as may be required by the
State, territory, locality, or Tribal area in
which they are prescribing, dispensing, or
administering COVID–19 vaccines;
v. The healthcare professionals and
students must have a current certificate in
basic cardiopulmonary resuscitation; 13
vi. The healthcare professionals and
students must comply with recordkeeping
and reporting requirements of the
jurisdiction in which he or she administers
vaccines, including informing the patient’s
13 This requirement is satisfied by, among other
things, a certification in basic cardiopulmonary
resuscitation by an online program that has
received accreditation from the American Nurses
Credentialing Center, the ACPE, or the
Accreditation Council for Continuing Medical
Education. The phrase ‘‘current certificate in basic
cardiopulmonary resuscitation,’’ when used in the
September 3, 2020 or October 20, 2020 OASH
authorizations, shall be interpreted the same way.
See Guidance for Licensed Pharmacists and
Pharmacy Interns Regarding COVID–19 Vaccines
and Immunity under the PREP Act, OASH, Sept. 3,
2020, available at https://www.hhs.gov/guidance/
sites/default/files/hhs-guidance-documents//
licensed-pharmacists-and-pharmacy-internsregarding-covid-19-vaccines-immunity.pdf (last
visited Jan. 24, 2021); Guidance for PREP Act
Coverage for Qualified Pharmacy Technicians and
State-Authorized Pharmacy Interns for Childhood
Vaccines, COVID–19 Vaccines, and COVID–19
Testing, OASH, Oct. 20, 2020, available at https://
www.hhs.gov/guidance/sites/default/files/hhsguidance-documents//prep-act-guidance.pdf (last
visited Jan. 24, 2021).
VerDate Sep<11>2014
16:45 Aug 03, 2021
Jkt 253001
primary-care provider when available,
submitting the required immunization
information to the State or local
immunization information system (vaccine
registry), complying with requirements with
respect to reporting adverse events, and
complying with requirements whereby the
person administering a vaccine must review
the vaccine registry or other vaccination
records prior to administering a vaccine; and
vii. The healthcare professionals and
students comply with any applicable
requirements (or conditions of use) as set
forth in the Centers for Disease Control and
Prevention (CDC) COVID–19 vaccination
provider agreement and any other federal
requirements that apply to the administration
of COVID–19 vaccine(s).
Nothing in this Declaration shall be
construed to affect the National Vaccine
Injury Compensation Program, including an
injured party’s ability to obtain compensation
under that program. Covered
countermeasures that are subject to the
National Vaccine Injury Compensation
Program authorized under 42 U.S.C. 300aa–
10 et seq. are covered under this Declaration
for the purposes of liability immunity and
injury compensation only to the extent that
injury compensation is not provided under
that Program. All other terms and conditions
of the Declaration apply to such covered
countermeasures.
2. Effective Time Period, section XII,
delete in full and replace with:
Liability protections for any respiratory
protective device approved by NIOSH under
42 CFR part 84, or any successor regulations,
through the means of distribution identified
in Section VII(a) of this Declaration, begin on
March 27, 2020 and extend through October
1, 2024.
Liability protections for all other Covered
Countermeasures identified in Section VI of
this Declaration, through means of
distribution identified in Section VII(a) of
this Declaration, begin on February 4, 2020
and extend through October 1, 2024.
Liability protections for all Covered
Countermeasures administered and used in
accordance with the public health and
medical response of the Authority Having
Jurisdiction, as identified in Section VII(b) of
this Declaration, begin with a Declaration of
Emergency as that term is defined in Section
VII (except that, with respect to qualified
persons who order or administer a routine
childhood vaccination that ACIP
recommends to persons ages three through 18
according to ACIP’s standard immunization
schedule, liability protections began on
August 24, 2020), and last through (a) the
final day the Declaration of Emergency is in
effect, or (b) October 1, 2024, whichever
occurs first.
Liability protections for all Covered
Countermeasures identified in Section VII(c)
of this Declaration begin on December 9,
2020 and last through (a) the final day the
Declaration of Emergency is in effect. or (b)
October 1, 2024. whichever occurs first.
Liability protections for Qualified Persons
under section V(d) of the Declaration who are
qualified pharmacy technicians and interns
to administer seasonal influenza vaccine to
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
persons aged 19 and older begin on August
4, 2021.
Liability protections for Qualified Persons
under section V(f) of the Declaration begin on
February 2, 2021, and last through October 1,
2024.
Liability protections for Qualified Persons
under section V(g) of the Declaration begin
on February 16, 2021, and last through
October 1, 2024.
Liability protections for Qualified Persons
who are physicians, advanced practice
registered nurses, registered nurses, or
practical nurses under section V(h) of the
Declaration begins on February 2, 2021 and
last through October 1, 2024, with additional
conditions effective as of March 11, 2021and
liability protections for all other Qualified
persons under section V(h) begins on March
11, 2021 and last through October 1, 2024.
Authority: 42 U.S.C. 247d–6d.
Dated: July 30, 2021.
Xavier Becerra,
Secretary, Department of Health and Human
Services.
[FR Doc. 2021–16681 Filed 8–2–21; 11:15 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Fogarty International Center; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Fogarty International
Center Advisory Board.
The meeting will be open to the
public via online meeting. Individuals
who plan to attend and need special
assistance, such as sign language
interpretation or other reasonable
accommodations, should notify the
Contact Person listed below in advance
of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Fogarty International
Center Advisory Board.
Date: September 9–10, 2021.
Closed: September 09, 2021, 12:00 p.m. to
3:30 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\04AUN1.SGM
04AUN1
Federal Register / Vol. 86, No. 147 / Wednesday, August 4, 2021 / Notices
Place: Fogarty International Center,
National Institutes of Health, 31 Center Drive,
Bethesda, MD 20892 (Virtual Meeting).
Open: September 10, 2021, 12:00 p.m. to
3:00 p.m.
Agenda: Update and discussion of current
and planned Fogarty International Center
activities.
Place: Fogarty International Center,
National Institutes of Health, 31 Center Drive,
Bethesda, MD 20892 (Virtual Meeting).
Meeting Access: https://www.fic.nih.gov/
About/Advisory/Pages/default.aspx.
Contact Person: Kristen Weymouth,
Executive Secretary, Fogarty International
Center, National Institutes of Health, 31
Center Drive, Room B2C02, Bethesda, MD
20892–7952, 301–496–1415,
kristen.weymouth@nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
www.fic.nih.gov/About/Advisory/Pages/
default.aspx, where an agenda and any
additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.106, Minority International
Research Training Grant in the Biomedical
and Behavioral Sciences; 93.154, Special
International Postdoctoral Research Program
in Acquired Immunodeficiency Syndrome;
93.168, International Cooperative
Biodiversity Groups Program; 93.934, Fogarty
International Research Collaboration Award;
93.989, Senior International Fellowship
Awards Program, National Institutes of
Health, HHS)
Dated: July 30, 2021.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–16607 Filed 8–3–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
lotter on DSK11XQN23PROD with NOTICES1
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
VerDate Sep<11>2014
16:45 Aug 03, 2021
Jkt 253001
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Fellowship:
Cardiovascular and Respiratory Sciences
Overflow.
Date: August 27, 2021.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Kimm Hamann, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4118A,
MSC 7814, Bethesda, MD 20892, (301) 435–
5575, hamannkj@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: July 30, 2021.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–16609 Filed 8–3–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Council on Drug Abuse.
The meeting will be held as a virtual
meeting and is open to the public, as
indicated below. Individuals who plan
to view the virtual meeting and need
special assistance or other reasonable
accommodations to view the meeting,
should notify the Contact Person listed
below in advance of the meeting. The
open session will be videocast and can
be accessed from the NIH Videocasting
and Podcasting website (https://
videocast.nih.gov/).
A portion of this will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
41983
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council on Drug Abuse.
Date: September 15, 2021.
Closed: 11:00 a.m. to 12:15 p.m.
Agenda: To review and evaluate grant
applications.
Open: 12:45 p.m. to 4:30 p.m.
Agenda: Presentations and other business
of the Council.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Susan R.B. Weiss, Ph.D.,
Director, Division of Extramural Research,
Office of the Director, National Institute on
Drug Abuse, NIH, Three White Flint North,
RM 09D08, 11601 Landsdown Street,
Bethesda, MD 20852, 301–443–6480, sweiss@
nida.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page:
www.drugabuse.gov/NACDA/
NACDAHome.html, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: July 29, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–16577 Filed 8–3–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Heart, Lung,
and Blood Advisory Council.
The meeting will be open to the
public as indicated below and held as
a virtual meeting. Individuals who plan
to view the virtual meeting and need
special assistance or other reasonable
accommodations to view the meeting,
should notify the Contact Person listed
below in advance of the meeting.
E:\FR\FM\04AUN1.SGM
04AUN1
]]>Agencies
[Federal Register Volume 86, Number 147 (Wednesday, August 4, 2021)]
[Notices]
[Pages 41982-41983]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-16607]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Fogarty International Center; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the Fogarty
International Center Advisory Board.
The meeting will be open to the public via online meeting.
Individuals who plan to attend and need special assistance, such as
sign language interpretation or other reasonable accommodations, should
notify the Contact Person listed below in advance of the meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Fogarty International Center Advisory Board.
Date: September 9-10, 2021.
Closed: September 09, 2021, 12:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant applications.
[[Page 41983]]
Place: Fogarty International Center, National Institutes of
Health, 31 Center Drive, Bethesda, MD 20892 (Virtual Meeting).
Open: September 10, 2021, 12:00 p.m. to 3:00 p.m.
Agenda: Update and discussion of current and planned Fogarty
International Center activities.
Place: Fogarty International Center, National Institutes of
Health, 31 Center Drive, Bethesda, MD 20892 (Virtual Meeting).
Meeting Access: https://www.fic.nih.gov/About/Advisory/Pages/default.aspx.
Contact Person: Kristen Weymouth, Executive Secretary, Fogarty
International Center, National Institutes of Health, 31 Center
Drive, Room B2C02, Bethesda, MD 20892-7952, 301-496-1415,
[email protected].
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Information is also available on the Institute's/Center's home
page: https://www.fic.nih.gov/About/Advisory/Pages/default.aspx,
where an agenda and any additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.106,
Minority International Research Training Grant in the Biomedical and
Behavioral Sciences; 93.154, Special International Postdoctoral
Research Program in Acquired Immunodeficiency Syndrome; 93.168,
International Cooperative Biodiversity Groups Program; 93.934,
Fogarty International Research Collaboration Award; 93.989, Senior
International Fellowship Awards Program, National Institutes of
Health, HHS)
Dated: July 30, 2021.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-16607 Filed 8-3-21; 8:45 am]
BILLING CODE 4140-01-P
